Barclays raised the firm’s price target on Arcellx to $62 from $49 and keeps an Overweight rating on the shares. Gilead and Arcellx this morning announced an expansion to their partnership, with Gilead opting in for BCMA Arc-SparX program for myeloma, and the companies expanding the CART-ddBCMA program to include lymphomas, the analyst tells investors in a research note. The firm says the timing and pricing bodes well for Arcellx’s near-term CART-ddBCMA update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACLX: